Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Receivables (2016 - 2025)

Biomerica's Receivables history spans 15 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Receivables fell 25.72% year-over-year to $2.0 million; the TTM value through Nov 2025 reached $2.0 million, down 25.72%, while the annual FY2025 figure was $1.5 million, 22.22% down from the prior year.
  • Receivables for Q4 2025 was $2.0 million at Biomerica, down from $2.5 million in the prior quarter.
  • Across five years, Receivables topped out at $3.7 million in Q2 2021 and bottomed at $772000.0 in Q1 2023.
  • The 5-year median for Receivables is $1.9 million (2021), against an average of $1.9 million.
  • The largest annual shift saw Receivables crashed 54.6% in 2022 before it skyrocketed 195.73% in 2024.
  • A 5-year view of Receivables shows it stood at $1.1 million in 2021, then rose by 21.93% to $1.4 million in 2022, then soared by 57.14% to $2.2 million in 2023, then grew by 24.26% to $2.7 million in 2024, then decreased by 25.72% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMRA's Receivables are $2.0 million (Q4 2025), $2.5 million (Q3 2025), and $1.5 million (Q2 2025).